Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

DR.REDDY'S LABORATORIES LTD (DRREDDY)
Mes dernières consult.
Most popular
  Report  
End-of-day quote. End-of-day quote  - 07/20
2058.6 INR   +1.55%
07/20DR REDDY LABORA : . Reddy’s Announces the Launch of Esomeprazo..
BU
07/17INDIVIOR : stock up
AQ
07/17INDIVIOR : Shares bounce back after legal victory
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Dr Reddy Laboratories : announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/14/2018 | 10:43am CEST

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced its intent to appeal the decision made by the U.S. District Court for the District of New Jersey in a preliminary injunction hearing with respect to further sales and commercialization of Dr. Reddy’s Buprenorphine and Naloxone Sublingual Film within the United States.

The company disagrees with the court’s decision, and will vigorously appeal it.

Dr. Reddy’s had announced the receipt of the approval, on June 15, 2018 by one of its wholly owned subsidiaries, from the U.S. Food and Drug Administration (USFDA) for its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, therapeutic equivalent generic version of Suboxone® (buprenorphine and naloxone) sublingual film, in the United States market.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR.REDDY'S LABORATORIES LT
10:25aDR REDDY LABORATORIES : Reddys launches Esomeprazole capsules
AQ
07/20DR REDDY LABORATORIES : . Reddy’s Announces the Launch of Esomeprazole Mag..
BU
07/17INDIVIOR : stock up
AQ
07/17TODAY'S RESEARCH REPORTS ON STOCKS T : Dr. Reddy's Laboratories and Intellia The..
AC
07/17DR REDDY LABORATORIES : Reddys shares tank 11% after US court decision on sale o..
AQ
07/17INDIVIOR : Shares bounce back after legal victory
AQ
07/17INDIVIOR : US ruling relief for Indivior as shares recover
AQ
07/16Indivior's shares soar 33 percent after U.S. court blocks sale of rival gener..
RE
07/14DR REDDY LABORATORIES : announces its intent to appeal court decision in prelimi..
BU
07/14INDIVIOR : wins preliminary injunction against generic rival
RE
More news
News from SeekingAlpha
07/20Dr. Reddy?s launches esomeprazole magnesium delayed-release capsules USP, 20 .. 
07/19Amazon entry into Indian pharmacy market a plus for local players - Morgan St.. 
07/18Court denies Dr. Reddy's stay on generic Suboxone ruling 
07/16HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (07/16/2018) 
07/16Dr. Reddy's down 8% premarket on injunction preventing U.S. launch of generic.. 
Financials (INR)
Sales 2019 159 B
EBIT 2019 19 644 M
Net income 2019 15 482 M
Debt 2019 26 494 M
Yield 2019 1,04%
P/E ratio 2019 21,83
P/E ratio 2020 16,15
EV / Sales 2019 2,28x
EV / Sales 2020 1,98x
Capitalization 335 B
Chart DR.REDDY'S LABORATORIES LT
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Technical analysis trends DR.REDDY'S LABORATORIES LT
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 39
Average target price 2 343  INR
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Erez Israeli Chief Operating Officer & Global Head-Generics
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR.REDDY'S LABORATORIES LTD-16.03%4 879
JOHNSON & JOHNSON-9.93%342 779
PFIZER3.06%220 295
NOVARTIS-1.75%206 001
ROCHE HOLDING LTD.-5.90%203 399
MERCK AND COMPANY11.11%169 328